Multimodal prehabilitation combining exercise, nutrition, and psychological support to improve chemotherapy response in early breast cancer
Official title: Multimodal Intervention During Neoadjuvant Chemotherapy in Patients With Early-breast Cancer as a Strategy to Improve Treatment Response: DIANA Trial (Multimodal Prehabilitation: DIet, ANxiety Control Psychotherapy, Physical Activity)
Run by Hospital Clinic of Barcelona · NCT07107594 · Data updated 2026-11-12
This trial will try a combined program of exercise, nutrition, and psychological support during neoadjuvant chemotherapy to see if it improves tumor response in women with early-stage (I–III) breast cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 214 (estimated) |
| Sponsor | Hospital Clinic of Barcelona Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Barcelona) |
| Status | Recruiting |
| Started | January 14, 2025 |
| Main results expected | January 2028 |
| Study ends | March 2028 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT07107594 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult women (≥18 years) with non-metastatic (stage I–III) breast cancer who are planned for neoadjuvant chemotherapy and are physically able to perform moderate-to-high intensity exercise.
✕Probably not a fit
Patients with metastatic (stage IV) disease, those unable to exercise safely, pregnant or breastfeeding women, men, or patients already doing more than 150 minutes per week of moderate-to-vigorous aerobic exercise are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial will enroll 214 women with non-metastatic (stage I–III) breast cancer who are scheduled for neoadjuvant chemotherapy and assign them 1:1 to either a multimodal prehabilitation program or standard care. The intervention group will receive structured physical exercise, nutritional guidance, and psychological support during the 4–6 months of chemotherapy, while the control group will receive routine clinical management. The primary comparison is the pathological response to chemotherapy at the time of surgery, with secondary outcomes likely including quality of life and treatment tolerance. The program seeks to optimize patients' physical and emotional condition and may favorably affect tumor microenvironment factors that influence treatment response.
Why it matters
Potential benefit: If successful, the program could increase rates of complete pathological response to neoadjuvant chemotherapy, potentially improving long-term outcomes and guiding postoperative treatment decisions.
How similar studies have gone: Individual components such as exercise, nutritional support, and psychological interventions have shown benefits for quality of life and treatment tolerance in breast cancer, but robust evidence that combined multimodal prehabilitation improves pathological chemotherapy response is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed diagnosis of non-metastatic breast cancer: stages cT1-T4, cN0-N3, M0, and candidates for neoadjuvant chemotherapy (NAC). * Age ≥ 18 years. * Signed informed consent. Exclusion Criteria: * Contraindication or physical inability to perform moderate-to-high intensity physical exercise. * Pregnant or breastfeeding patients. * Presence of other active synchronous neoplasms. * Metastatic breast cancer (stage IV). * Patients already engaging in regular physical exercise: more than 150 minutes of moderate or intense aerobic exercise per week. * Male breast cancer patients. * Personal history of a previous malignancy treated with chemotherapy. * Severe or poorly controlled psychiatric illness (including uncontrolled active substance abuse).
Where it's running
-
Hospital Clínic de Barcelona
Barcelona, Spain Recruiting
Study contacts
- Study coordinator: Helena Castillo Espín, MD
- Email: hcastillo@clinic.cat
- Phone: +34 651024667
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Regular exercise to help women with early-stage breast cancer on hormone therapy
This study tests whether a guided, 16-week exercise program improves quality of life and fitness for women with early-stage breast cancer who are starting adjuvant hormone therapy.
-
Preoperative functional optimization for adults undergoing major cardiac or abdominal surgery
This study tests a four‑week prehabilitation program to improve fitness before elective major cardiac or abdominal surgery.
-
Multimodal Prehabilitation for Gastric Cancer Patients
This program tests whether a combined pre- and post-operative wellness plan can reduce inflammation after gastric cancer surgery in adults.
-
Wireless home prehabilitation for older adults with NSCLC awaiting lung surgery
This study tests whether a personalized home exercise program guided by wearable devices can improve lung function for older NSCLC patients preparing for curative lung surgery.
-
Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer
This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.
-
Feasibility of high-dose multimodal prehabilitation for women awaiting gynecologic cancer surgery
This study tests whether a high-dose, multimodal prehabilitation program can be delivered before gynecologic cancer surgery and whether patients prefer in-person, remote, or education-only approaches.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.